Unity Biotechnology, Inc. (UBX)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of Mar 14, 2025

$1.77

P/E Ratio

N/A

Market Cap

$29.86M

Description
Add to research
View more

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.

Metrics
Add to research
View more

Overview

  • HQSouth San Francisco, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerUBX
  • Price$1.77-1.12%

Trading Information

  • Market cap$29.86M
  • Float91.21%
  • Average Daily Volume (1m)112,778
  • Average Daily Volume (3m)254,861
  • EPS-$1.54

Company

  • RevenueN/A
  • Rev growth (1yr)N/A
  • Net income-$25.99M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$27.86M
  • EV$16.74M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B4.60
  • Debt/Equity362.47
Documents
Add to research
View more